Wuhan Vanz Pharm Inc.

 

Wuhan Vanz Pharm Inc., Your reliable supplier!

Home
Products
About Us
Factory Tour
Quality Control
Contact Us
Request A Quote
Home ProductsNootropic Supplements

99% Purity NSI-189 Freebase Nootropic Supplements CAS 1270138-40-3

Good quality Pharmaceutical Intermediates for sales
Good quality Pharmaceutical Intermediates for sales
I am very happy to cooperate with your company for nearly three years, thank you very attentive service, thank you for the excellent product quality.

—— Stephnie

You always have very fast delivery, very happy to cooperate with you. Thank you.

—— John

Very pleased to become your customer, and very happy for our cooperation, hope to be your long-term parter.

—— Sara

we received the package, very fast, the quality is very good, will continue to buy your products.

—— Luice

I have emailed you a couple times and they get returned as undeliverable. Yes. I am happy with the powders. thank you.

—— Bryan

I'm Online Chat Now

99% Purity NSI-189 Freebase Nootropic Supplements CAS 1270138-40-3

China 99% Purity NSI-189 Freebase Nootropic Supplements CAS 1270138-40-3 supplier
99% Purity NSI-189 Freebase Nootropic Supplements CAS 1270138-40-3 supplier 99% Purity NSI-189 Freebase Nootropic Supplements CAS 1270138-40-3 supplier

Large Image :  99% Purity NSI-189 Freebase Nootropic Supplements CAS 1270138-40-3

Product Details:

Place of Origin: China
Brand Name: VANZ
Certification: ISO9001
Model Number: NSI-189

Payment & Shipping Terms:

Minimum Order Quantity: 10g
Price: USD 0.5- 1 Per Gram
Packaging Details: 10g, 100g, 1kg aluminum seal bag
Delivery Time: 3-7 Days
Payment Terms: Western Union, MoneyGram, T/T
Supply Ability: 10kg Per Month
Contact Now
Detailed Product Description
CAS: 1270138-40-3 Appearance: White Powder
Application: Nootropic Grade: Medicine Grade
Sample: Available COA: Available

99% Purity NSI-189 Freebase Nootropic Supplements CAS 1270138-40-3

 

 

NSI-189 is neurogenic and nootropic research agent that was developed from nicotinamide and pyrazine. Randomized controlled trials have shown that it stimulates neurogenesis or neuronal cell production in the brain. In animal studies, NSI-189 has also been shown to increase the volume of hippocampus by 20% thereby reversing behavioral symptoms of depression. Such studies have shown that it may be an effective treatment for depression. NSI-189 is also thought to be a promising treatment for other condition including post-traumatic stress disorder (PTSD), Alzheimer’s disease and age-related cognitive problems. 

 

Neuralstem's technology enabled the creation of neural stem cell lines from many areas of the human CNS, including the hippocampus. The hippocampus is a part of the brain involved in memory and the generation of new neurons. It is also implicated in several major neurological and psychiatric diseases. From its hippocampal neural stem cell lines, Neuralstem has created virtually unlimited amounts of mature human neurons and glia in laboratory dishes. These can be used to mimic the natural brain environment in order to test drug effects.

 

Neuralstem has been engaged in its own drug discovery program with these human hippocampal stem cell lines since 2000. In 2009, Neuralstem was granted U.S. patents on four first-in-class chemical entities that boost the generation of new neurons. NSI-189, the first of these to be in a clinical trial, significantly stimulates the generation of new hippocampal neurons (neurogenesis) in vitro and in animal models, above and beyond the neural stem cells' innate differentiation.

 

NSI-189 is the lead compound in Neuralstem's neuroregenerative small molecule drug platform, which the company plans to develop into orally administered drugs for MDD and other psychiatric disorders, such as Alzheimer's disease, anxiety, bipolar disorder and post traumatic stress disorder.

NSI-189 stimulated neurogenesis of human hippocampus-derived neural stem cells in-vitro. In healthy normal adult mice, NSI-189 stimulated neurogenesis in the hippocampus and significantly increased its volume, apparently by increasing its synaptic network after 28 days of daily oral administration. In mouse models of depression, NSI-189 significantly improved behavioral responses associated with depression. In humans, NSI-189 may reverse the human hippocampal atrophy seen in MDD and other disorders and reverse their symptoms. This program has received significant support from both the Defense Advanced Research Projects Agency (DARPA) and the National Institutes of Health (NIH).

 

Basic Information

Product name nsi-189
Cas 1270138-40-3
MF: C22H30N4O
MW: 366.4998
Appearance: White fine powder
Application Medicine or health care products
Purity: 99%min
 

 

About the Trial

The NSI-189/MDD trial is a randomized, double-blind, placebo-controlled, multiple-dose escalating trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamic effect of NSI-189 in the treatment of MDD. Phase Ia tested escalating doses of single administration of NSI-189 in healthy patients. Phase Ib will test the safety of escalating doses of NSI-189 for 28 daily administrations in 24 depressed patients. The Phase Ib portion of the trial is expected to take approximately six months to complete.

 

 

About Neuralstem

Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem is in an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's disease and has been awarded orphan status designation by the FDA.

In addition to ALS, the company is also targeting major central nervous system conditions with its cell therapy platform, including spinal cord injury, ischemic spastic paraplegia, chronic stroke, and Huntington's disease. The company has submitted an IND (Investigational New Drug) application to the FDA for a Phase I safety trial in chronic spinal cord injury.

Neuralstem also has the ability to generate stable human neural stem cell lines suitable for the systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain's capacity to generate new neurons, possibly reversing the pathologies of some central nervous system conditions. The company has received approval from the FDA to conduct a Phase Ib safety trial evaluating NSI-189, its first small molecule compound, for the treatment of major depressive disorder (MDD). Additional indications could include schizophrenia, Alzheimer's disease and bipolar disorder.

99% Purity NSI-189 Freebase Nootropic Supplements CAS 1270138-40-3

Contact Details
Wuhan Vanz Pharm Inc.

Contact Person: Amy

Tel: +8613277095342

Send your inquiry directly to us (0 / 3000)